UBS OCONNOR LLC - INOZYME PHARMA INC ownership

INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 74 filers reported holding INOZYME PHARMA INC in Q2 2023. The put-call ratio across all filers is 2.65 and the average weighting 0.2%.

Quarter-by-quarter ownership
UBS OCONNOR LLC ownership history of INOZYME PHARMA INC
ValueSharesWeighting
Q3 2023$652,281
-24.6%
155,3050.0%0.02%
-40.7%
Q2 2023$865,049
+2.2%
155,305
+5.2%
0.03%
+3.8%
Q1 2023$846,057
-99.8%
147,654
-10.8%
0.03%
+225.0%
Q3 2022$444,000,000
-45.7%
165,498
-3.4%
0.01%
-33.3%
Q2 2022$817,000,000171,3470.01%
Other shareholders
INOZYME PHARMA INC shareholders Q2 2023
NameSharesValueWeighting ↓
Pivotal bioVenture Partners Investment Advisor LLC 1,591,154$18,441,0006.52%
CHI Advisors LLC 920,264$10,666,0003.11%
Sofinnova Investments, Inc. 2,028,308$23,508,0001.39%
MPM BioImpact LLC 320,724$3,717,0000.58%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,344,786$27,176,0000.53%
NEA Management Company, LLC 2,444,379$28,330,0000.34%
Rock Springs Capital Management LP 850,015$9,852,0000.21%
SUVRETTA CAPITAL MANAGEMENT, LLC 986,400$11,432,0000.19%
Overbrook Management Corp 16,726$194,0000.04%
Orbimed Advisors 294,000$3,407,0000.04%
View complete list of INOZYME PHARMA INC shareholders